

cancer

disease


science

next
generation

TCRmTM

**TCRmTM Potency Assay
Services**

Receptor Logic is revolutionizing health and life through the its proprietary T-Cell Receptor mimic (TCRmTM) technology accelerating research and commercial solutions in the current and emerging life sciences and healthcare markets.



targeting **health & life**

TCRm™ Potency Assay Services

Targeting the critical need for potency measurements, our services provide biopharma partners quantitative solutions for their immunotherapeutic products.

Receptor Logic, Inc. has developed a new class of monoclonal antibodies, T-Cell Receptor mimic monoclonal antibodies (TCRms) that offer a ready solution to active immunotherapy potency assays. TCRms recognize specific MHC-peptide complexes with avidities similar to the best cytotoxic T-lymphocyte (CTL) lines classically used in activity assays.

The impressive specificity of TCRm antibodies coupled with their ability to recognize validated disease biomarkers, in the form of discrete MHC-peptide complexes, establish these reagents as new tools to augment and/or replace T-cell based assays. TCRm-based methods measure <40 MHC-peptide complexes containing a specific, bound epitope on a cell, or expressed in a different manner, detection of <0.05% of an expressed MHC allele. TCRms facilitate product potency measurements by:

- Assisting lead antigen validation
- Correlating antibody reactivity with T-cell function
- Substituting TCRm assays for T-cell-based approaches
- Demonstrating lot-to-lot consistency for released drug substance
- Testing product stability

TCRm™ Platform Versatility

TCRms can be adapted to flow cytometry, ELISA and surface plasmon resonance formats. TCRm binding assays quantitate the number of specific peptide epitopes presented by a particular MHC molecule and correlate this number with specific T-cell or other biological activity. Once this correlation is established, TCRms provide:

- Soluble, archival reagents
- Flexible assay formats
- Reproducible, quantitative results reflecting biological activity
- Cost-effective use
- Methods adaptable for Quality Control validation

TCRm-based methods also provide a quantitative baseline value for historically semi-quantitative assays, including ELISPOT, cell proliferation and CTL approaches.



An Emergent Company

Management services are provided by Emergent Technologies, Inc. (ETI). ETI, founded in 1989, is a life sciences venture capital firm that specializes in forming, funding, commercializing, and managing companies for the purpose of converting institutional and university-based technologies into high return ventures.

Business Opportunity

Contact us to discover the value Receptor Logic can add to your therapeutic pipeline. Receptor Logic seeks strategic co-development partnerships with leading biotechnology and pharmaceutical companies.

11412 Bee Caves Rd, Ste 300
Austin, TX 78738
(t) 512.697.8146
(f) 512.263.3236
info@receptorlogic.com

www.receptorlogic.com